Armata Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded grant and award revenue of $2.5 million for the second quarter, a 15.7% increase from $2.2 million in the same period last year. For the first half of 2026, total revenue reached $3.3 million, up 24% from $2.7 million in the first half of 2025. Despite this revenue growth, Armata's operating expenses surged to $12.8 million in Q2 2026, a 42.3% increase compared to $9.0 million in Q2 2025, primarily driven by higher research and development costs and general administrative expenses. The company reported a net income of $74.1 million for the quarter, a stark contrast to a net loss of $16.3 million in the prior year, largely due to a significant gain from the change in fair value of its Convertible Loan.
In terms of operational changes, Armata has made strategic moves to bolster its financial position. The company entered into a $25 million secured term loan agreement in May 2026, which is set to mature in January 2029. This loan, along with amendments to existing credit agreements, has extended the maturity dates of several loans to June 2027. Additionally, Armata has utilized its At-the-Market (ATM) offering to raise approximately $2.4 million by issuing 338,000 shares during the first half of 2026. These financing activities are crucial as the company anticipates needing additional capital to fund ongoing research and development efforts.
Armata's operational metrics indicate a focus on advancing its clinical pipeline, particularly its bacteriophage-based therapies. The company has completed three Phase 2 clinical trials and is preparing for a pivotal Phase 3 study for its lead product candidate, AP-SA02, targeting complicated Staphylococcus aureus bacteremia. The company is also exploring additional indications for its products, including potential treatments for prosthetic joint infections. As of June 30, 2026, Armata had an accumulated deficit of $542.7 million, reflecting its ongoing investment in research and development.
Looking ahead, Armata's management has expressed concerns regarding its ability to continue as a going concern, given that its existing cash and cash equivalents of $24 million are insufficient to fund operations for the next 12 months. The company plans to raise additional capital through various means, including public and private equity offerings, debt financing, and strategic partnerships. However, management acknowledges that these plans are subject to market conditions and may not be realized, which could impact the company's ability to execute its development programs.
Overall, Armata Pharmaceuticals is navigating a complex financial landscape while advancing its innovative bacteriophage therapies. The company's recent financial performance reflects both growth in revenue and significant operational challenges, underscoring the need for continued capital investment to support its ambitious clinical development goals.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. Its lead candidates, AP-PA02 and AP-SA02, focus on chronic pulmonary infections caused by Pseudomonas aeruginosa and acute Staphylococcus aureus bacteremia, respectively. Utilizing proprietary phage discovery, engineering, and cGMP manufacturing, Armata aims to offer safer, targeted alternatives to broad-spectrum antibiotics for difficult-to-treat infections in specialized patient populations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov